Yes, Nexletol Treats High Cholesterol
Nexletol (bempedoic acid) is an FDA-approved oral medication for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL cholesterol reduction. It targets primary hyperlipidemia, a common form of high cholesterol, and is used alongside diet, exercise, and often statins when those alone aren't enough.[1]
How Nexletol Lowers Cholesterol
Nexletol inhibits ATP citrate lyase, an enzyme in the liver's cholesterol synthesis pathway upstream from statins' target (HMG-CoA reductase). This reduces LDL-C by 17-28% as monotherapy or add-on therapy, based on phase 3 trials like CLEAR Harmony and CLEAR Wisdom.[1][2] It's taken once daily at 180 mg, with effects seen in 4 weeks.
Who Qualifies for Nexletol
Prescribed for:
- HeFH patients (genetic high cholesterol).
- ASCVD patients (e.g., post-heart attack) with LDL-C ≥70 mg/dL on max-tolerated statins.
- Statin-intolerant patients due to muscle pain.
Not for primary prevention in low-risk high cholesterol without ASCVD or HeFH.[1]
Nexletol vs. Statins and Other Options
| Treatment | Mechanism | LDL-C Reduction | Common Use Case |
|-----------|-----------|-----------------|---------------|
| Nexletol | ACL inhibitor | 17-28% | Add-on or statin alternative |
| Statins (e.g., atorvastatin) | HMG-CoA reductase inhibitor | 20-60% | First-line for most high cholesterol |
| Ezetimibe | Cholesterol absorption blocker | 15-25% | Combo with statins |
| PCSK9 inhibitors (e.g., Repatha) | LDL receptor enhancer (injection) | 50-70% | High-risk refractory cases |
Nexletol pairs well with ezetimibe (as NEXLIZET) for up to 38% LDL-C drop.[1][3]
Common Side Effects and Patient Concerns
Most frequent: Increased uric acid (5-10%, risking gout), muscle spasms (3-7%), back pain, and diarrhea. Tendon rupture risk is low (0.5%) but higher in those over 60 or on steroids. Liver enzyme elevations occur in <2%; monitor annually. No muscle breakdown like rhabdomyolysis seen with statins.[1][2]
Cost, Access, and Patent Status
List price ~$2,675/month (180 mg daily), but copay cards reduce to $10-30 for eligible insured patients. Patents expire around 2029-2033; check DrugPatentWatch.com for updates on challenges or generics.[4]
[1] Nexletol Prescribing Information, Esperion Therapeutics (FDA-approved Feb 2020).
[2] CLEAR Outcomes Trial, NEJM (2023).
[3] NEXLIZET Prescribing Information.
[4] DrugPatentWatch.com - Bempedoic Acid Patents